NCT06165302Recruiting
Exercise in Prostate Cancer
EPC Trial: Exercise in Prostate Cancer
Source: ClinicalTrials.gov · Last updated 29 Oct 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn how exercise intervention affects circulating tumor cells (CTC) in men with advanced prostate cancer. The primary objective is to determine if an exercise intervention decreases CTCs in men with advanced prostate cancer. Participants will have baseline screening assessments, followed by 12 weeks of exercise intervention, and then follow-up assessments 12 weeks after the end of the exercise intervention.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 1 Dec 2023
- Start date
- 16 Oct 2025
- Primary completion date
- 1 Mar 2029
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Diseases
- Prostate cancer
- NCT number
- NCT06165302
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 16 Oct 2025 to the primary completion date, 1 Mar 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Clinical progression requiring a change in systemic therapy or the addition of palliative radiation for symptom control
- Bone metastases in spine or long bones which, in the eye of the treating physician require referral to radiation oncology or surgery for management due to risk of fracture
- Significant cardiovascular disease or concurrent illness that would make exercise intervention for 12 weeks unsafe. If there is significant cardiovascular disease and the participant is under the care of a cardiologist (seen within the past 1 year), approval of the cardiologist to participate is required.
- Major surgery within the past 4 weeks
Other illness
- Unable to participate or monitor exercise compliance due to conditions such as impaired cognition
- Moderate to severe bone pain, including pain requiring the use of narcotics for prostate cancer related pain, or pain that limits any activities of daily living
Other
- Small cell carcinoma of the prostate
Who the study is looking for
- Men with metastatic prostate adenocarcinoma
- Currently taking androgen deprivation therapy alone or with an oral androgen axis inhibitor (abiraterone, enzalutamide, darolutamide, or apalutamide are permitted) and have been on treatment for at least 3 months
- Elevated (PSA \>= 1ng/mL) or rising PSA (any numerical increase based on at least 2 PSA readings at least 2 weeks apart)
- Any number of prior therapies (prior chemo, radium-223, etc.) is allowed
- CTC + at screening
- If a bone protective agent is to be started, it should be started at least 2 weeks prior to the onset of exercise intervention.
- Eastern Cooperative Oncology Group (ECOG) performance status \<=1
- Clearance by cardiologist if under the current care of a cardiologist (seen in the past 1 year)
- Determined to be physically ready for exercise by PM\&R physician
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Johns Hopkins University Coordinator of this site? Confirm its status | Baltimore | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.